TIM-3 would also have a specific inhibitory role in antitumour immunity: it is, indeed, widely expressed on tumour antigen-specific T lymphocytes, both at the peripheral blood level and at the level of tumour-infiltrating lymphocytes (TILs), either CD4+ or CD8+ [11]. The gene discussed is CD8A; the disease is neoplasm.